STOCK TITAN

Walgreens Launches Inaugural Patient Advisory Board to Advance Access and Representation in Clinical Research

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management clinical trial

Walgreens has launched its inaugural Clinical Trials Patient Advisory Board, consisting of 10 patient experts who will serve 2-year terms. The board will collaborate with the Walgreens Clinical Trials team to enhance representation in clinical research, particularly focusing on historically excluded communities.

Since launching in June 2022, the Clinical Trials team has reached over 7 million patients for potential recruitment into sponsor-led trials. This initiative addresses significant challenges in clinical research, as only 5% of the U.S. population participates in clinical trials, and nearly 80% of trials fail to meet enrollment goals.

Walgreens ha lanciato il suo Consiglio Consultivo per i Pazienti nelle Sperimentazioni Cliniche, composto da 10 esperti pazienti che svolgeranno un mandato di 2 anni. Il consiglio collaborerà con il team di Sperimentazioni Cliniche di Walgreens per migliorare la rappresentanza nella ricerca clinica, concentrandosi in particolare sulle comunità storicamente escluse.

Dall'avvio nel giugno 2022, il team di Sperimentazioni Cliniche ha raggiunto oltre 7 milioni di pazienti per potenziali reclutamenti in studi sponsorizzati. Questa iniziativa affronta sfide significative nella ricerca clinica, poiché solo il 5% della popolazione statunitense partecipa a sperimentazioni cliniche e quasi 80% degli studi non raggiunge gli obiettivi di arruolamento.

Walgreens ha lanzado su Consejo Asesor de Pacientes para Ensayos Clínicos, compuesto por 10 expertos pacientes que cumplirán mandatos de 2 años. El consejo colaborará con el equipo de Ensayos Clínicos de Walgreens para mejorar la representación en la investigación clínica, centrándose particularmente en comunidades históricamente excluidas.

Desde su lanzamiento en junio de 2022, el equipo de Ensayos Clínicos ha llegado a más de 7 millones de pacientes para posibles reclutamientos en ensayos patrocinados. Esta iniciativa aborda desafíos significativos en la investigación clínica, ya que solo el 5% de la población de EE.UU. participa en ensayos clínicos, y casi el 80% de los ensayos no logra cumplir con los objetivos de inscripción.

월그린스는 10명의 환자 전문가로 구성된 첫 번째 임상 시험 환자 자문위원회를 발족했습니다. 위원들은 2년 임기를 수행하며, 위원회는 월그린스 임상 시험 팀과 협력하여 임상 연구에서의 대표성을 향상시키고, 특히 역사적으로 배제된 커뮤니티에 중점을 두게 됩니다.

2022년 6월 출범 이후, 임상 시험 팀은 700만 명 이상의 환자에게 접근하여 스폰서가 주도하는 시험에 참여할 수 있는 가능성을 모색하고 있습니다. 이 이니셔티브는 임상 연구에서 중요한 과제를 해결하며, 미국 인구의 5%만이 임상 시험에 참여하고, 거의 80%의 시험이 모집 목표를 달성하지 못하는 현황에 주목합니다.

Walgreens a lancé son premier Conseil Consultatif des Patients pour les Essais Cliniques, composé de 10 experts patients qui serviront des mandats de 2 ans. Le conseil collaborera avec l'équipe des Essais Cliniques de Walgreens pour améliorer la représentation dans la recherche clinique, en se concentrant particulièrement sur les communautés historiquement exclues.

Depuis son lancement en juin 2022, l'équipe des Essais Cliniques a atteint plus de 7 millions de patients pour un recrutement potentiel dans des essais sponsorisés. Cette initiative vise à répondre à des défis significatifs dans la recherche clinique, car seulement 5% de la population américaine participe à des essais cliniques, et près de 80% des essais échouent à atteindre leurs objectifs de recrutement.

Walgreens hat sein inaugural Patientenbeirat für klinische Studien ins Leben gerufen, der aus 10 Patientsexperten besteht, die 2 Jahre lang tätig sein werden. Der Beirat wird mit dem Walgreens-Team für klinische Studien zusammenarbeiten, um die Vertretung in der klinischen Forschung zu verbessern, insbesondere mit Fokus auf historisch ausgegrenzte Gemeinschaften.

Seit der Gründung im Juni 2022 hat das Team für klinische Studien über 7 Millionen Patienten erreicht, um sie für die Teilnahme an gesponserten Studien zu gewinnen. Diese Initiative zielt darauf ab, erhebliche Herausforderungen in der klinischen Forschung anzugehen, da nur 5% der US-Bevölkerung an klinischen Studien teilnehmen, und fast 80% der Studien die Einschreibungsziele nicht erreichen.

Positive
  • Reached over 7 million potential clinical trial participants since June 2022
  • Established dedicated Patient Advisory Board with 10 expert members
  • Strategic initiative to address the 80% trial enrollment failure rate
Negative
  • Current low 5% U.S. population participation rate in clinical trials

The Walgreens Patient Advisory Board will collaborate with the Walgreens Clinical Trials team to provide insights aimed at increasing representation in clinical trials.

DEERFIELD, Ill.--(BUSINESS WIRE)-- With a history of more than 120 years serving communities across the country, Walgreens prides itself in being a trusted retail pharmacy partner for more than 9 million patients and customers it serves each day. Walgreens is amplifying its commitment to its patients and partners through the formation of the Walgreens Clinical Trials Patient Advisory Board. Since its launch in June 2022, the Walgreens Clinical Trials team has reached more than 7 million patients to potentially recruit into sponsor-led clinical trials. As the team continues expanding its scope and raising awareness about the importance of community-centered clinical research, the Patient Advisory Board members will offer key patient insights that are an invaluable resource to the delivery and advancement of clinical trials.

The inaugural Patient Advisory Board consists of 10 patient experts who will leverage both lived and learned experiences to inform clinical trial recruitment and retention efforts to increase access and representation in clinical research in communities that have historically been excluded. Ramita Tandon, chief biopharma services officer, is standing up the Board as part of Walgreens’ commitment to bringing community-based clinical research to more people that may benefit from it.

“I am proud to engage with our inaugural cohort of Patient Advisory Board members to increase awareness and representation in clinical trials. Only 5% of the U.S. population participates in clinical trials and nearly 80% of trials fail to meet their enrollment goals, often contributing to delays in bringing new medications to patients,” said Tandon. “Our Patient Advisory Board members will help inform how we approach our sponsor-led clinical trials to better serve our patients and partners.”

With increasing regulatory focus on incorporating patients’ perspectives in medical product development,1,2 and the growth of precision medicine,3 now more than ever, it’s important to engage with patients and individuals who have had experience with clinical research as their lived experiences offer an opportunity to continue improving clinical trials to best serve patients.

Walgreens Clinical Trials Patient Advisory Board members will commit to serve a 2-year term and will offer ongoing counsel, diverse thinking and expertise to inform Walgreens Clinical Trials efforts.

Learn more about Walgreens Clinical Trials here. ​

About Walgreens ​

Founded in 1901, Walgreens (www.walgreens.com) has a storied heritage of caring for communities for generations, and proudly serves nearly 9 million customers and patients each day across its approximately 8,500 stores throughout the U.S. and Puerto Rico, and leading omni-channel platforms. Walgreens has approximately 220,000 team members, including nearly 90,000 healthcare service providers, and is committed to being the first choice for retail pharmacy and health services, building trusted relationships that create healthier futures for customers, patients, team members and communities.​

Walgreens is the flagship U.S. brand of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy and retail leader. Its retail locations are a critical point of access and convenience in thousands of communities, with Walgreens pharmacists playing a greater role as part of the healthcare system and patients’ care teams than ever before. Walgreens Specialty Pharmacy provides critical care and pharmacy services to millions of patients with rare disease states and complex, chronic conditions.

  1. Patient Engagement Collaborative. https://www.fda.gov/patients/learn-about-fda-patient-engagement/patient-engagement-collaborative
  2. Patient-Focused Drug Development: Workshop to Discuss Methodologic and Other Challenges Related to Patient Experience Data. December 13, 2024 https://www.fda.gov/drugs/news-events-human-drugs/patient-focused-drug-development-workshop-discuss-methodologic-and-other-challenges-related-patient
  3. https://www.biospace.com/press-releases/precision-medicine-market-size-to-reach-usd-470-53-billion-by-2034

Carmen Lopez

Walgreens Media Relations

media@walgreens.com

Source: Walgreens

FAQ

What is the purpose of Walgreens (WBA) new Patient Advisory Board?

The Walgreens Patient Advisory Board aims to increase representation and access in clinical trials, particularly focusing on historically excluded communities, by providing patient insights for recruitment and retention efforts.

How many patients has Walgreens (WBA) Clinical Trials team reached since June 2022?

The Walgreens Clinical Trials team has reached more than 7 million patients for potential recruitment into sponsor-led clinical trials since June 2022.

What is the current participation rate in clinical trials according to WBA?

According to Walgreens, only 5% of the U.S. population currently participates in clinical trials.

How long will WBA Patient Advisory Board members serve?

Walgreens Clinical Trials Patient Advisory Board members will commit to serve a 2-year term.

What percentage of clinical trials fail to meet enrollment goals according to WBA?

According to Walgreens, nearly 80% of clinical trials fail to meet their enrollment goals.

Walgreens Boots Alliance, Inc

NASDAQ:WBA

WBA Rankings

WBA Latest News

WBA Stock Data

8.07B
711.67M
17.66%
61.81%
11.66%
Pharmaceutical Retailers
Retail-drug Stores and Proprietary Stores
Link
United States of America
DEERFIELD